178 related articles for article (PubMed ID: 38382468)
21. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
23. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
24. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
25. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
27. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Jiang C; Yuan F; Wang J; Wu L
Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
[TBL] [Abstract][Full Text] [Related]
28. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
29. The role of the immunoescape in colorectal cancer liver metastasis.
Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
[TBL] [Abstract][Full Text] [Related]
30. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis.
Melotti S; Ambrosi F; Franceschini T; Giunchi F; Filippo GD; Franchini E; Massari F; Mollica V; Tateo V; Bianchi FM; Colecchia M; Acosta AM; Lobo J; Fiorentino M; Ricci C
Pathol Res Pract; 2023 Jul; 247():154540. PubMed ID: 37209574
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated macrophages and PD-L1 in prostate cancer: a possible key to unlocking immunotherapy efficacy.
Wang J; Wu W; Yuan T; Wang L; Zang L; Liu Q; Wang L; Huo X; Huo B; Tang Y; Wang H; Zhao Z
Aging (Albany NY); 2024 Jan; 16(1):445-465. PubMed ID: 38189834
[TBL] [Abstract][Full Text] [Related]
32. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
Front Immunol; 2021; 12():693881. PubMed ID: 34552581
[TBL] [Abstract][Full Text] [Related]
33. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
Tsuruta A; Shiiba Y; Matsunaga N; Fujimoto M; Yoshida Y; Koyanagi S; Ohdo S
Mol Cancer Res; 2022 Jun; 20(6):972-982. PubMed ID: 35190830
[TBL] [Abstract][Full Text] [Related]
34. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
35. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
36. Dynamic alteration and prognostic significance of tumor-associated CD68
Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG
Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
Chen TW; Hung WZ; Chiang SF; Chen WT; Ke TW; Liang JA; Huang CY; Yang PC; Huang KC; Chao KSC
Cancer Lett; 2022 Sep; 543():215795. PubMed ID: 35718267
[TBL] [Abstract][Full Text] [Related]
38. Lymph node and tumor-associated PD-L1
Sprooten J; Vanmeerbeek I; Datsi A; Govaerts J; Naulaerts S; Laureano RS; Borràs DM; Calvet A; Malviya V; Kuballa M; Felsberg J; Sabel MC; Rapp M; Knobbe-Thomsen C; Liu P; Zhao L; Kepp O; Boon L; Tejpar S; Borst J; Kroemer G; Schlenner S; De Vleeschouwer S; Sorg RV; Garg AD
Cell Rep Med; 2024 Jan; 5(1):101377. PubMed ID: 38232703
[TBL] [Abstract][Full Text] [Related]
39. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
